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Galectins are highly expressed in epithelial cells and immune cells. In skin, they can be detected in
keratinocytes, melanocytes, dendritic cells, macrophages, and T cells. Galectins are present outside and
inside the cells and thus may exhibit different functions through extracellular and intracellular actions.
Galectins can be involved in the pathogenesis of inﬂammatory skin diseases by affecting growth,
apoptosis, maturation, activation, and motility of keratinocytes and immune cells. Expression of galectins
may change depending on the cellular status, such as proliferation and activation. For example, galectin-
3 expression is upregulated in T cells but downregulated in dendritic cells when these cells are activated.
Furthermore, their expression may also change under pathological conditions. Understanding the
function of each galectin in keratinocytes and different immune cell types may reveal how galectins
contribute to the pathogenesis of immune-mediated skin diseases.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Galectins are a family of lectins containing one or two conserved
carbohydrate-recognition domains (CRDs) that preferentially bind
to b-galactosides.1 Galectins are expressed widely among different
organisms, including mammals, insects, sponges, fungi, and
nematodes. Structurally, galectins can be classiﬁed into three types:
single-CRD galectins composed of approximately 130 amino acids;
double-CRD galectins containing two homologous CRDs separated
by a linker of up to 70 amino acids; and galectin-3, which contains
one CRD following a nonlectin region of about 120 amino acids
composed of tandem repeats of short proline/glycine-rich
sequences. This proline/glycine rich region is believed to partici-
pate in the formation of galectin-3 pentamers upon binding of the
lectin to multivalent carbohydrates.2 Single-CRD galectins can form
homo-dimers and thus can be functionally bivalent, while double-
CRD galectins are intrinsically bivalent.3
Galectins do not contain a classical signal sequence but can be
secreted through an as yet undeﬁned secretory pathway and
detected in the extracellular space. The proteins are known to be
localized in the cytoplasm and can move into the nucleus or be
associated with intracellular vesicles under certain conditions.4 The
distribution of galectins between cytoplasm and nucleus dependsiences, Academia Sinica, 128
n.
.
iwanese Dermatological Associatioon the cell types and proliferative status.5 Modiﬁcation of galectins,
such as phosphorylation may also contribute to the subcellular
localization.6
Since galectins can exist both outside and inside the cells, their
functions may differ depending on their location. Galectins may
work extracellularly in an autocrine or paracrine manner to
modulate cell status or functions, e.g., activation of cells, mediation
of cellecell and celleextracellular matrix interactions, and
promotion of cell migration.7,8 These extracellular effects may
result from cross-linkage of glycoproteins on the cell surfaces due
to galectins’ bivalency or oligovalency with regard to carbohydrate
binding. The resulting structures have been termed “galectin
lattices” and their formation can alter the properties of the glyco-
proteins involved, for example restricted lateral mobility on the cell
surface, thus modulating responses mediated through them.9
Intracellularly, galectins can function in a carbohydrate-
independent manner to regulate cell apoptosis, migration, and
responses to stimuli.4,8 In the nucleus, galectins can be involved in
pre-mRNA splicing by functioning as components of spliceo-
somes10 and regulation of the expression of certain genes.11
Galectins in the biological responses of skin cells
Galectin-1
Galectin-1 is composed of a 14 kDa CRD and exists as monomers or
homodimers. It has wide tissue distribution and is differentially
expressed by different tissues in normal and pathologicaln. Published by Elsevier Taiwan LLC. All rights reserved.
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keratinocytes, Langerhans cells, and ﬁbroblasts. It is also abun-
dantly present in the extracellular matrix in the dermis.13
Keratinocytes
Galectin-1 is primarily located along the plasma membrane of
keratinocytes.13 Previous studies have provided evidence that
galectin-1 has the potential to mediate cellematrix interactions by
binding to cell adhesion molecules and extracellular matrix
proteins, suggesting a role in cell migration, re-epithelialization,
and wound healing.14,15
Dvoránková et al16 showed that administration of galectin-1
had a positive effect on skin wound healing in rats. Galectin-1
can induce the conversion of dermal ﬁbroblasts into myoﬁbro-
blasts and production of extracellular matrix, thus contributing to
support keratinocyte growth and promoting wound healing.
However, in another study, Cao et al17 showed that both endoge-
nous galectin-1 and exogenously added galectin-1 do not affect the
re-epithelialization rate of corneal wounds.
Fibroblasts
By immunostaining and in situ hybridization, galectin-1 was found
to be expressed in both the nucleus and cytoplasm of ﬁbroblasts in
the dermis.13 The expression of galectin-1 in ﬁbroblasts has been
associated with the transdifferentiation of ﬁbroblasts to myoﬁ-
broblasts and the production of extracellular matrix.16,18
Expression of galectin-1 in ﬁbroblasts affects tumor progression
and metastasis. Wu et al19 found that galectin-1 knockdown
decreased ﬁbroblast activation and extracellular matrix production.
Furthermore, galectin-1 knockdown signiﬁcantly reduced
carcinoma-associated ﬁbroblast-augmented tumor growth and
metastasis, possibly by modulating MCP-1 expression. These
results suggest that galectin-1 in cancer-associated ﬁbroblasts may
be a target for cancer therapy.
Langerhans cells
In human skin, galectin-1 has also been detected in the cytoplasm
and nucleus of Langerhans cells in the epidermis.13 Fulcher et al20
showed that galectin-1 treatment stimulated human dendritic
cell (DC) maturation and triggered expression of genes related to
cell migration through the extracellular matrix by upregulation of
multiple matrix metalloproteinase genes. An additional study
identiﬁed the underlying mechanisms and showed that galectin-1
co-clustered surface CD43 and CD45 on DCs and induced cell
activation and migration through Syk and protein kinase C
signaling.21 Intradermal injection of galectin-1 also enhanced
in vivo migration of dermal DCs to draining lymph nodes in the
autoimmune MRL-fas mice.21 These results suggest that galectin-1
may contribute to initiation of an immune response in part by
regulating DC migration.
Galectin-3
Galectin-3 is mainly expressed in inﬂammatory and epithelial
cells.8 Cells expressing galectin-3 in the skin include DCs, macro-
phages, T cells, keratinocytes, mast cells, hair follicles, sebaceous
and eccrine glands, melanocytes, and ﬁbroblasts.8
Keratinocytes
Galectin-3 is present in the cytoplasm of normal keratinocytes.22
Upon differentiation of keratinocytes, the expression of galectin-3
is upregulated.23 Galectin-3 has been shown to be limited in the
suprabasal layers of epidermis and be colocalizedwith desmosomal
proteins.24 These ﬁndings suggest that galectin-3 expression is
associated with keratinocyte differentiation and maturation.Another study also concluded that expression of galectin-3 is
correlated to the status of keratinocyte differentiation.23 Galectin-3
binds to laminin and enhances keratinocyte cell motility.
Galectin-3 has been shown to exhibit anti-apoptosis function in
ultraviolet-B (UVB) irradiation-induced apoptosis in mouse kera-
tinocytes. UVB can induce galectin-3 expression in keratinocytes
and galectin-3 suppresses extracellular-regulated kinase (ERK)
activation and enhances Akt activation in apoptosis-related
responses.25 Recombinant galectin-3 has been shown to induce
keratinocyte migration possibly through an extracellular interac-
tionwith b4 integrin, epidermal growth factor receptor (EGFR), and
laminin on the keratinocyte matrix.26 Our group has recently found
that galectin-3 regulates intracellular trafﬁcking of EGFR in kera-
tinocytes. Gal3/ keratinocytes have a lower expression of EGFR
and this results in lower cell migration and slower wound re-
epithelialization in mice.27
T cells
Functions of galectin-3 in T cells has been recently reviewed.28
Extracellular galectin-3 can form lattices with the T-cell receptor
(TCR) complex and negatively regulate TCR-mediated signal trans-
duction.29 Extracellular galectin-3 can also induce T cell apoptosis.30
Analyses of galectins in T cell proliferation have recently shown that
galectin-1 and galectin-8 can costimulate T cell proliferation, while
galectin-3 fails to costimulate and instead antagonizes galectin-1-
and galectin-8-facilitated T cell responses.31 An endogenous func-
tion of galectin-3 recently shown by our group is related to its
recruitment to the immunological synapse, where it can play
a negative role in the T cell response upon TCR engagement.32 The
function of galectin-3 in the immunological synapse may involve its
binding partner, Alix, which is associated with endosomal sorting
complex required for transport.
Macrophages
Galectin-3 has been shown to activate and promote adhesion of
myeloid cells,8 function as a chemoattractant for humanmonocytes
and macrophages,33 and play a critical role in alternative macro-
phage activation.34 Galectin-3 was found to contribute to FcgR-
mediated phagocytosis of red blood cells and translocate to the
phagosomes in cells that have engulfed red blood cells.35 Galectin-3
binds to dectin-1 receptor on macrophage and affects tumor
necrosis factor-a secretion in cells infected with Candida albicans.36
Dendritic cells
Galectin-3 was found to be expressed in either immature or mature
DCs. Endogenous galectin-3 has been shown to drive DCs into
a Th2-promoting phenotype, as gal3/ DCs secrete a higher level
of interleukin (IL)-12 cytokine, which is a potent Th1-polarizing
cytokine.37 Galectin-3 also plays a negative role in DC function in
stimulating T cell activation.38 Another proposed function of
galectin-3 is that it can inhibit allogeneic T cell responses or induce
higher levels of apoptosis in T cells through DCs.39 Galectin-3 also
affects motility of DCs as gal3þ/þ DCs migrate faster than gal3/
DCs in vitro and in vivo.40
Fibroblasts
Expression of galectin-3 was shown to increase in proliferating
ﬁbroblasts compared to quiescent cells.41 Since exogenously added
galectin-3 can strongly stimulate colonic ﬁbroblast growth,42 this
protein may also be able to stimulate ﬁbroblasts in the skin.
Galectin-7
Compared to other more commonly studied galectins, galectin-7,
a one-CRD galectin, exhibits a higher degree of tissue speciﬁcity;
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correlates with keratinocyte differentiation.43e45
Several studies have provided evidence to suggest a role of
galectin-7 inmaintenance of epithelial homeostasis. Galectin-7was
identiﬁed as an early transcriptional target responding to tumor
suppressor gene p53 overexpression.46 UVB irradiation is an efﬁ-
cient modulator of p53 gene expression and Bernerd et al47 found
that galectin-7 mRNA and protein were induced rapidly in kerati-
nocytes exposed to UVB irradiation, in parallel with p53 stabiliza-
tion and apoptosis induction. In addition, galectin-7 overexpression
results in keratinocyte cell death. These ﬁndings suggest that
galectin-7 may be related to the pro-apoptotic function of p53.
Kuwabara et al48 demonstrated that ectopic expression of galectin-
7 in HeLa cells rendered themmore sensitive to apoptosis triggered
by various stimuli. Furthermore, galectin-7 transfectants displayed
accelerated mitochondrial cytochrome c release and upregulated
JNK activity upon apoptosis induction. Galectin-7 is also involved in
the corneal wound healing process,17 especially in re-
epithelialization of wounds, probably through modulating corneal
epithelial cell migration.49 Such a role for galectin-7 in the
homeostatic control of epithelia is supported by a recent study
using galectin-7-deﬁcient mice: Gendronneau et al50 showed that
galectin-7 helped maintain epidermal homeostasis in response to
UVB irradiation and wounding by modulating keratinocyte
apoptosis and proliferation as well as participating in the process of
cell migration.
Villeneuve et al51 identiﬁed galectin-7 as a new mitochondrial
Bcl-2-interacting protein. A fraction of galectin-7 is constitutively
localized to mitochondria, partially dependent on Bcl-2 expression.
Moreover, overexpression of mitochondrial galectin-7 sensitizes
mitochondria in response to apoptotic stimuli, enhancing the
release of cytochrome c and Smac/DIABLO. These ﬁndings suggest
that upon dissociation of galectin-7 and Bcl-2 complexes, the pro-
apoptotic function of galectin-7 is uncovered, leading to the initi-
ation of the apoptotic cascade. Furthermore, galectin-7 expression
was found to be upregulated in transgenic mice expressing extra-
cellular superoxide dismutase. The upregulation of galectin-7 may
be regulated through the production of COX-2 and results in
apoptosis in the epidermis.52
Galectin-8
Galectin-8 is a tandem-repeat type of galectin that is highly
expressed in endothelial cells of lymphatic vessels compared to
blood vessels and interacts with podoplanin to support the inter-
action of lymphatic endothelium with the surrounding extracel-
lular matrix.53
The C-terminal CRD can bind to polyLacNAc glycans on T cells
and cause phosphatidylserine (PS) exposure, which occurs inde-
pendently of apoptosis.54 Galectin-8 can induce T cell apoptosis via
an ERK1/2-mediated pathway.55 However, galectin-8 has also been
reported to exhibit two distinct biological activities on T cells, an
antigen-independent T cell proliferation and an antigen-dependent
co-stimulatory effect.56
Galectin-8 has been shown to be expressed on platelets and
induce platelet activation by binding to certain glycoproteins on
platelets.57 Galectin-8 can stimulate endothelial cell migration and
capillary cell formation, and thus plays a role in angiogenesis.58
Galectin-8 has recently been shown to play a role against bacte-
rial infection in macrophages through induction of autophagy.59
Galectin-9
Human galectin-9 was ﬁrst identiﬁed from the Hodgkin’s disease-
involved spleen.60 At least 10-fold higher expression of galectin-9mRNA was detected in lymphatic tissues from Hodgkin’s disease
patients compared to those from normal individuals.60 Moreover,
the fact galectin-9 is highly expressed in normal immune system,
such as spleen, thymus, lymph nodes, and peripheral blood
leukocytes,61 suggests that it may be involved in the immune
response or the pathogenesis of immune diseases.
Studies showed that galectin-9 can be produced by human T cell
lines and has eosinophil chemoattractant activity.61,62 Recombinant
galectin-9 induces apoptosis in mouse thymocytes, activated CD4
and CD8 T cells, and various T, B, and monocytic cell lines.63,64
Apoptosis in those cells through calcium-calpain-caspase-1-
dependent and -independent pathways.64,65 T-cell immunoglob-
ulin mucin domain 3, speciﬁcally expressed in Th1 T cells but not
Th2 T cells, is an effective ligand for galectin-9.66 Binding of
galectin-9 to the extracellular domain of T-cell immunoglobulin
mucin domain 3 leads to Th1 cell apoptosis.66
Several studies have demonstrated that recombinant galectin-9
suppresses Th1 and Th17 responses, and promotes
Foxp3þCD25þCD4þ regulatory Tcell differentiation and proliferation.
In different animal models of inﬂammatory diseases, such as exper-
imental autoimmune encephalomyelitis,67rheumatoid arthritis,68
complex immune-induced arthritis,69 collagen-induced arthritis,70
allergic asthma,71 nephritis,72 diabetic nephropathy,73 contact
dermatitis,74 psoriasis,74 diabetes,75,76 andgraft versushost disease,77
galectin-9 has been shown to have a suppressive function inTh1- and
Th17-mediated immunity.
Galectin-12
Galectin-12 has been found mainly in adipocytes and plays a role in
adipocyte differentiation in vitro78 and lipolysis.79 It has also been
found in sebaceous gland in human skin.80 The function of galectin-
12 in sebocytes is unknown.
Figure 1 summarizes the effects of galectins on the biological
responses of skin cells.
Role of galectins in cutaneous immune disorders
Galectin-1
Acute inﬂammation
Galectin-1 is emerging as a powerful modulator in both innate and
adaptive immune responses.8,12 In a model of acute inﬂammation,
administration of galectin-1 suppressed bee venom phospholipase
A2-induced inﬂammatory responses, which was correlated with
diminished numbers of inﬁltrating neutrophils and scarce degra-
nulated mast cells.81 The antiinﬂammatory effect was also assessed
in vitro, where galectin-1 treatment resulted in reduced inﬂam-
matory mediator release from peritoneal macrophages. Further-
more, the role of endogenous galectin-1 in acute inﬂammation was
investigated by using gal1/ mice. In a carrageenan-induced
model of edema, gal1/ mice displayed an attenuated edema.82
This reduced inﬂammatory response was associated with lower
expression of inﬂammatory cytokines and cellular inﬁltrates, and
increased apoptosis of inﬁltrating leukocytes. The role of endoge-
nous galectin-1 during the initiation and resolution of acute
inﬂammation may result from the balance of different biological
effects and remains to be further investigated.
Contact hypersensitivity
In addition to its role in innate immune responses and acute
inﬂammation, galectin-1 also participates in adaptive immunity
and chronic inﬂammation. Targeted overexpression of galectin-1 in
DCs signiﬁcantly increased the sensitization phase of contact
hypersensitivity, while inducing a drastic inhibition of the
Figure 1 The effects of galectins (Gal) on the biological responses of skin cells.
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dermis.83
In a mouse model of hapten-mediated contact hypersensitivity,
galectin-1-treatment alleviated T cell-dependent inﬂammation,
and exhibited a marked decrease in interferon-g (IFNg)þ and IL-
17þT cells and increase in regulatory T cells.84 Further analyses
showed that galectin-1 treatment skewed the Th2 response by
upregulating IL-4 and IL-10 expression, and triggering apoptosis in
the Th1 and Th17 subsets. Furthermore, Cedeno-Laurent et al85
provided a detailed molecular mechanism by which galectin-1
exhibits immunosuppressive activity in resolving inﬂammatory
responses. Direct binding of galectin-1 to CD45 on activated T cells
stimulates IL-10 synthesis and enhances IL-21 expression through
the c-Maf/AhR pathway. Galectin-1-induced IL-10-expressing T
cells (termed type 1 regulatory T cells, which produce IL-10, but do
not express FOXP3) effectively suppress T cell proliferation and
ameliorate skin inﬂammation in a mouse model of allergic contact
dermatitis. These results, along with the information mentioned
above, suggest that galectin-1 is an anti-inﬂammatory mediator of
skin inﬂammation in contact hypersensitivity.
Psoriasis
A few studies have examined the correlation between galectins and
psoriasis. De la Fuente et al86 investigated the expression and role
of galectin-1 (as well as galectins-3 and -9) in psoriatic skin.
Compared with normal individuals, lower levels of galectin-1 were
found in both lesional and nonlesional skin samples from psoriasis
patients. Galectin-1 expression was downregulated in Langerhans
cells and dermal DCs as well as in peripheral blood myeloid DCs
from psoriasis patients. Together with the previous studies in
animal models,87 this suggests an important role for galectin-1 in
the immunopathogenesis of psoriasis. In addition, exogenous
addition of galectin-1 attenuated the Th1 response, which may
involve the secretion of the suppressive cytokines, such as IL-10,
from DCs. It is suggested that galectin-1 downregulation may
contribute to the exacerbation of the inﬂammatory responses in
psoriasis.86
Galectin-1 (as well as galectins-3 and -9) is highly expressed in
Langerhans cells in the skin of healthy donors. However, it is
expressed at lower levels in the skin of psoriatic patients. Higher
levels of Th1/Th17 cytokines were also detected in psoriatic skin.86
The lower level of galectin-1 was considered a factor contributing
to psoriasis, as exogenously added galectin-1 attenuated the Th1
response in a coculture of patient monocyte-derived DCs andautologous T cells. Blockade of the galectin-1 binding resulted in
higher levels of IFNg and lower levels of IL-10. The authors thus
hypothesized that galectin-1 downregulation contributes to the
exacerbation of the Th1/Th17 effector response in psoriasis
patients.86
Galectin-3
The roles of galectin-3 in inﬂammation and skin diseases have been
extensively studied.7,12 These include induction of cell activation,
regulation of cellular homeostasis, and promotion of cell adhesion
as well as cell migration.
Atopic dermatitis
Atopic dermatitis is a chronic inﬂammatory skin condition that
involves a predominant Th2 cytokine milieu in the initiating stages
of atopic dermatitis and a mixed Th1 and Th2 pattern in chronic
lesions.88 Our laboratory has studied the effects of endogenous
galectin-3 in the development of allergic skin inﬂammation in mice
induced by repeated epicutaneous sensitization with ovalbumin
(OVA). Gal3/ mice did not exhibit as much epidermal thickening
as gal3þ/þmice and developed lower eosinophil inﬁltrations, lower
serum IgE levels, and a lower Th2, but higher Th1 response
compared to gal3þ/þmice. Moreover, mice receiving gal3/ T cells
expressing OVA-speciﬁc T cell receptor and then epicutaneously
sensitized with OVA developed a lower Th2 response and lower
skin inﬂammation than mice that received gal3þ/þ T cells. These
results suggest that galectin-3 is a proinﬂammatory mediator of
skin inﬂammation in atopic skin disease.89
Contact dermatitis
In a study of gene expression of responses to nickel in reconstructed
human epidermis, galectin-3 expression has been shown to be
suppressed in epidermal keratinocytes.90 Our laboratory has also
found that endogenous galectin-3 contributes positively to allergic
contact dermatitis in mice when comparing gal3/ mice and
gal3þ/þ mice.40 It is possible that galectin-3 contributes to contact
dermatitis through DCs, as gal3/ DCs showed a reduced migra-
tory phenotype compared to gal3þ/þ DCs.
Psoriasis
Lacina et al91 investigated the expression of galectin-3 (as well as
galectins-1 and -7) and their glycoligands in psoriatic skin
compared to normal skin. Galectin-3 expression was lower in
Table 1 Roles of galectins (Gal) in cutaneous immune disorders.
Acute inﬂammation:
Gal 1: suppresses bee venom phospholipase A2-induced inﬂammatory
responses
Gal 1: promotes carrageenan-induced edema
Atopic dermatitis (AD):
Gal 3: promotes allergic inﬂammation and Th2 response
Contact hypersensitivity (CD):
Gal 1: increases the sensitization phase of contact hypersensitivity
Gal 1: Inhibits the elicitation phase by triggering apoptosis in T cells in the
dermis
Gal 1: induces regulatory T cells and ameliorates skin inﬂammation
Gal 3: promotes CD response, possibly through enhancing dendritic cells
migration
Gal 9: suppresses CD response. reduces Th 1 and Th 17 responses
Psoriasis:
Gal 1: suppresses Th 1 and Th 17 responses
Gal 9: reduces epidermal thickness, dermal cellular in ﬁltrates, and the levels
of cytokines in treated skin lesions
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galectin-3 and galectin-3-reactive glycoligands were found to be
strongly expressed in the capillary epithelia of psoriatic dermis,
indicating that galectin-3 and galectin-3-reactive glycoligands may
be involved in dermal capillary rearrangement and inﬂammatory
cell recruitment.91
Galectin-9
In a mouse model of contact dermatitis, a Th1- and Th17-mediated
disease, the inﬂammation response of ear swelling was suppressed
by recombinant galectin-9.74 In this study, recombinant galectin-9
induced apoptosis in CD4 and CD8 T cells and reduced the number
of IFNg and IL-17-producing Tcells.74 Psoriasis is another skin disease
that is mediated by Th1 and Th17 responses. In the IL-23-induced
psoriasis mouse model, recombinant galectin-9 reduced epidermal
thickness, dermal cellular inﬁltrates, and decreased the levels of IL-
17, IL-22, IL-6 and tumor necrosis factor-a in treated skin lesions.74
This suggests that galectin-9 plays a therapeutic role in psoriasis.
However, the study investigating the function of galectin-9 dealt
with exogenously added recombinant galectin-9. One key issue is
whether endogenous galectin-9 also plays a signiﬁcant role in
pathogenesis of psoriasis. De la Fuente et al compared the expres-
sion levels of galectin-9 in nonlesional and lesional skin samples
from 24 psoriasis patients and 10 control samples by RT-PCR anal-
ysis, but found no difference in galectin-9 expression among these
samples.86 One possibility is that galectin-9 is only expressed in
speciﬁc cell types in skin tissue; therefore, the procedure was not
able to detect the changes in galectin-9 expression in a subset of
cells, when analyzing the whole tissues containing a mixture of
cells. Indeed, when evaluating the galectin-9 expression in human
skin by immunohistochemistry, Igawa et al found signiﬁcant
galectin-9 expression in dermal ﬁbroblasts in the lesions of psoriasis
patients.92 Meanwhile, a signiﬁcant number of eosinophils were
found to be attached to dermal ﬁbroblasts in the lesions.92 Since it
has been shown that galectin-9 has eosinophil chemoattractant
activity and IFNg induces galectin-9 expression in ﬁbroblasts and
endothelial cells in vitro,93,94 it is possible that during pathogenesis
of psoriasis, IFNg produced by Th1 T cells stimulates galectin-9
expression in dermal ﬁbroblasts and the expression of galectin-9
promotes adhesion of eosinophils in the dermis.92
Galectin-9 is expressed by Langerhans cells and peripheral
myeloid DCs in normal human skin and blood.86 Recombinant
galectin-9 was shown to promote maturation of human monocyte-
derived DCs.95 In addition, galectin-9-treated DCs secrete IL-12 but
not IL-10, and enhance the production of Th1 cytokines by alloge-
neic CD4þ Tcells.95 Therefore, this suggests that galectin-9 is able to
induce DC maturation and promote Th1 immune responses. To
investigate the relationship between galectin-9 and psoriasis in
human DCs, de la Fuente et al found that more severe disease
indexes of psoriasis were associated with slightly lower expression
levels of galectin-9 in myeloid DCs, but the difference was not
statistically signiﬁcant.86
Galectin-9 is also constitutively expressed in human epidermal
keratinocytes.92 In contrast with dermal ﬁbroblasts, the expression
of galectin-9 in keratinocytes is dose-dependently inhibited by
IFNg in vitro.92 Interestingly, epidermal cells from lesions of Th2-
dominated bullous pemphigoid disease showed strongly positive
staining of galectin-9 in the cytoplasm of keratinocyte.92
Moreover, galectin-9 is expressed in amousemast cell lineMC/9
and in human cord blood-derived mast cells.96,97 It is known that
mast cells play an important role in pathogenesis of allergic contact
dermatitis.98 Galectin-9 binds to IgE and attenuates the activation
of mast cells in vitro.99 Furthermore, recombinant galectin-9 sup-
pressed passive cutaneous anaphylaxis in mice, which is an in vivomodel for examining the degranulation of mast cells.96 These data
indicate that galectin-9 is a regulator of mast cell activity and the
function of galectin-9 in mast cells might be involved in the
development of dermatitis.
Taken together, expression of galectin-9 in different cell types
might result in different inﬂammatory responses in skin. Further
studies are necessary to elucidate the expression patterns and
functions of endogenous galectin-9 in different cell types in
different inﬂammatory skin disorders.
The roles of galectins in cutaneous immune disorders are
summarized in Table 1.
Conclusions
Galectins are now known to contribute to fundamental cellular
responses in skin under normal and inﬂammation status and they
do so by functioning inside or outside the cells. For those galectins
with immunosuppressive effects, soluble recombinant proteins
may be useful for treatment of autoimmune and inﬂammatory
diseases. For those galectins implicated in diseases, their inhibitors
may be used to treat these diseases. The issue is whether the
proteins work inside or outside the cells, as that will determine
whether the inhibitors should target intracellular or extracellular
galectins. However, the functions of galectins inside and outside the
cells may be difﬁcult to distinguish.
In general, functions of galectins outside the cells may involve
their carbohydrate-binding activity and those inside the cells may
involve proteineprotein, rather than proteineglycan interactions.
The possible existence of intracellular galectin-glycan interactions
has been revealed by a study suggesting that galectin-8 induces
autophagosomes inmacrophages infected by Salmonella by binding
to cytosolic glycans.59 The authors hypothesized that these glycans
are present in the lumen of endosomes containing engulfed
bacteria that become exposed to the cytosol after the bacteria lyse
the endosomes. The glycans on the ruptured membrane can then
be recognized by cytosolic galectin-8, which is followed by the
formation of macromolecular complexes involving other intracel-
lular proteins culminating in autophage. Whether binding of
galectins to intracellular glycans in a similar fashion occurs under
other pathological conditions and contributes to the pathogenesis
of diseases remains to be delineated.
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